Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
New York, NY, June 19, 2026 (GLOBE NEWSWIRE) -- Two student entrepreneurs from NFTE’s New York Metro Youth Entrepreneurship Showcase will advance to the U.S. National Youth Entrepreneurship Showcase...
-
ELIZABETH, NJ, June 18, 2026 (GLOBE NEWSWIRE) -- Game On!, a community-centered initiative designed to connect residents with the excitement and opportunities surrounding the FIFA World Cup 2026™,...
-
UNIONDALE, N.Y., June 17, 2026 (GLOBE NEWSWIRE) -- Duffy & Duffy, PLLC, one of New York's leading medical malpractice and personal injury law firms, is proud to announce that numerous attorneys...
-
Lord Jameson returns to its roots with With Love From, New York, a limited-edition USDA Organic dog treat available exclusively in New York State.
-
UNIONDALE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- A Long Island man who now walks with a cane because of permanent nerve damage caused by chemotherapy has been awarded $400k for past pain and...
-
Fair Lawn, NJ, June 10, 2026 (GLOBE NEWSWIRE) -- Brookaire published a new guide for HVAC contractors, facility managers, and building engineers who deal with odor and gas complaints that...
-
CLAY, N.Y., June 10, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU) and Bechtel announced today that Micron has selected Bechtel to partner on the engineering, procurement and...
-
Newport Beach, CA, June 05, 2026 (GLOBE NEWSWIRE) -- Bimergen Energy Corporation [NYSE American: BESS, BESS.WS] today announced that Bob Brilon, Co-CEO will participate in The Small Cap Showcase...
-
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- RYTHM and The Daily Green are kicking off the Summer of RYTHM sweepstakes, a two month consumer promotion featuring exclusive rewards and a chance to win...
-
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...